ArticleScientific reports2025
African swine fever vaccine ASFV-G-ΔI177L induces solid protection in four-week-old piglets.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel B cell epitopes mapping in pD205R protein of African swine fever virus using monoclonal antibodies.BMC veterinary research · 2026Article
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is an important disease of swine currently affecting pig production worldwide. Vietnam is, currently, the only country where commercial live attenuated vaccines are being freely used in the field. One of these vaccines is based in the use of the ASFV-G-ΔI177L strain, a recombinant virus developed by a partial deletion in the I177L gene from the highly virulent parental strain Georgia 2010. The commercial version of the vaccine was originally limited to use in pigs between 8 and 10 weeks of age, which significantly restricts its use. In this report, we demonstrate that pigs can be vaccinated as early as the fourth week of age, producing an efficacious immune response that fully protects the animals against the challenge with the virulent Vietnamese field strain TTKN/ASFV/DN/2019 and thus increasing the vaccine's usage to pigs 4-10 weeks of age. Several groups of four-week-old pigs were intramuscularly (IM) vaccinated with a single dose of a commercial vaccine containing 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.